Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 2 examiners • 0 of 4 (0%) have an AI response strategy ready
BASF Corporation has 4 pending office actions in Biotechnology & Pharmaceuticals. The docket involves 2 examiners and 2 art units, with KOVALENKO, MYKOLA V handling 3 pending matters.
The concentration with one examiner makes that examiner’s treatment a central prosecution consideration. Counsel can look for consistent positions across the three matters while separately addressing the action assigned to the other examiner and art unit.
The two-art-unit distribution also supports technical grouping of the work, but it does not eliminate the need to track application-specific claim scope, cited references, and response deadlines.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOVALENKO, MYKOLA V | 3 | 69.6% | +25.5% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695023 | IMAZAMOX AND GLYPHOSATE FOR CONTROLLING DIGITARIA INSULARIS | SCOTLAND, REBECCA LYNN | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15156671 | HERBICIDE-TOLERANT PLANTS | KOVALENKO, MYKOLA V | 34d |
| 13393744 | Herbicide-Tolerant Plants | KOVALENKO, MYKOLA V | — |
| 13393784 | HERBICIDE-TOLERANT PLANTS | KOVALENKO, MYKOLA V | — |
| Art Unit | Apps |
|---|---|
| 1662 | 3 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695023 | IMAZAMOX AND GLYPHOSATE FOR CONTROLLING DIGITARIA INSULARIS | SCOTLAND, REBECCA LYNN | 1615 | §103§112 | Final Rejection | 5d | Pending | Mar 25, 2024 |
| 15156671 | HERBICIDE-TOLERANT PLANTS | KOVALENKO, MYKOLA V | 1662 | DP | Final Rejection | 34d | Pending | May 17, 2016 |
| 13393744 | Herbicide-Tolerant Plants | KOVALENKO, MYKOLA V | 1662 | §103 | Final Rejection | — | Pending | Jul 20, 2012 |
| 13393784 | HERBICIDE-TOLERANT PLANTS | KOVALENKO, MYKOLA V | 1662 | §112DP | Non-Final OA | — | Pending | Jul 20, 2012 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBASF Corporation has 4 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Mykola V Kovalenko has the most, with 3 of BASF Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
